Work

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)

Year: 2004

Type: article

Study design: Case Report

Source: Leukemia

DOI: 10.1038/sj.leu.2403548

Authors: R L Levine, M Wadleigh, D W Sternberg, I Wlodarska, I Galinsky, R M Stone, D J DeAngelo, D Gary Gilliland, J Cools

Institutions: Brigham and Women's Hospital, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute, Icahn School of Medicine at Mount Sinai, Vlaams Instituut voor Biotechnologie, KU Leuven

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Howard Hughes Medical Institute, National Institutes of Health, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: G2852253759, G3409028890, G409126305, Abnormalities/Signal Transduction/Hematopoietic Disease, SIGNAL TRANSDUCTION BY TEL/TYROSINE KINASE FUSIONS, Development of Novel Therapeutic Strategies in Human Leukemias

OpenAlex ID: W2001737705

FWCI: 4.578

Cites: 25

Cited by: 57

Related to: 10